Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
ConclusionsThe CRAFITY score is simple and could be useful for predicting therapeutic outcomes and treatment-related adverse events.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Avastin | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Immunotherapy | Infectious Diseases | Japan Health | Liver | Liver Cancer | Proteinuria | Study | Urology & Nephrology